Cabozantinib manufacturers and suppliers in india

Cabozantinib

CAS:: 849217-68-1

MF:: C28H24FN3O5

MW:: 501.51

Suppliers by country/region

Company Type

Properties

Melting point:: 212-215°C

Boiling point:: 758.1±60.0 °C(Predicted)

Density: 1.396

storage temp.: -20°C

solubility: Soluble in DMSO

form: White powder.

pka: 13.86±0.70(Predicted)

color: White

Stability:: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.

InChIKey: ONIQOQHATWINJY-UHFFFAOYSA-N

SMILES: C1(C(NC2=CC=C(OC3C4C(N=CC=3)=CC(OC)=C(OC)C=4)C=C2)=O)(C(NC2=CC=C(F)C=C2)=O)CC1

Safety Information

Symbol(GHS): GHS05

Signal word: Danger

Hazard statements: H315-H318

Precautionary statements: P264-P280-P302+P352-P321-P332+P313-P362-P280-P305+P351+P338-P310

Use

In clinical trials, common adverse effects caused by cabozantinib include diarrhea, stomatitis, palmar-plantarrythrodysesthesia syndrome (PPES), and loss of weight, loss of appetite, nausea, fatigue, oral pain, taste disorders, high blood pressure, abdominal pain and constipation. The most common laboratory abnormalities ( 25%) were increased aspartate aminotransferase, alanine aminotransferase, lymphopenia, increased alkaline phosphatase level, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia and hyperbilirubinemia. For patients receiving cabozantinib, 57% of patients have gotten increased level of thyroid stimulating hormone after initial dose, compared with patients receiving placebo, increased by 19%. Information regarding to the anticancer drug, mechanism of action, pharmacokinetics, side effects, and drug interactions of cabozantinib were compiled and edited by Yan Shi from Chemicalbook. (2015-10-23)